XML 6 R1.htm IDEA: XBRL DOCUMENT v3.21.4
Cover
Dec. 20, 2021
Document Type 8-K/A
Amendment Flag true
Amendment Description This Amendment No. 1 on Form 8-K/A amends the Current Report on Form 8-K of Humacyte, Inc. (the "Original Report"), which reported the departure of Jeffrey H. Lawson, M.D., PhD. as the Company's Chief Surgical Officer and Dr. Lawson's resignation from the Company's board of directors, each effective as of the "separation date." The Original Report contained a scrivener error and incorrectly stated the separation date as December 31, 2022. The correct separation date is December 31, 2021.
Document Period End Date Dec. 20, 2021
Entity File Number 001-39532
Entity Registrant Name Humacyte, Inc.
Entity Central Index Key 0001818382
Entity Tax Identification Number 85-1763759
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 2525 East North Carolina Highway 54
Entity Address, City or Town Durham
Entity Address, State or Province NC
Entity Address, Postal Zip Code 27713
City Area Code 919
Local Phone Number 313-9633
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Common Stock [Member]  
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol HUMA
Security Exchange Name NASDAQ
Redeemable Warrants Each Whole Warrant Exercisable For One Share Of Common Stock At Exercise Price Of11.50 [Member]  
Title of 12(b) Security Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50
Trading Symbol HUMAW
Security Exchange Name NASDAQ